和铂医药-B(02142)今日盘中大涨7.39%,引发市场关注。据分析,造成这一现象的主要原因有两点:
第一,和铂医药近期宣布与Windward Bio签订独家授权协议,对方可在特定地区拥有HBM9378/SKB378抗体产品的全球独家许可。这项协议将为和铂医药带来最高9.7亿美元预付款及里程碑付款,以及未来销售分成收入,体现了公司在医药领域良好的商业前景。
第二,和铂医药上月初宣布回购计划,拟动用最多4000万港元在公开市场回购公司股份,董事会一致认为公司股票当前市场价格严重低估。这一舆情反映了公司对自身未来发展前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.